• Novartis to Build Fourth US Radioligand Therapy Plant in Florida
BASEL, Switzerland – Novartis announced on January 9 its plans to construct a new radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, which is expected to be operational by 2029.
The facility is the fourth of its kind for the company in the United States and is intended to expand production capacity for its cancer treatments.
What is new?
Novartis will build a new manufacturing site in Winter Park, Florida, dedicated to radioligand therapy (RLT), a specialized form of cancer treatment. The announcement, made on January 9, 2026, confirms the project is part of a previously declared $23 billion investment in the United States.
The facility aims to meet the growing demand for RLT treatments and improve delivery to patients, particularly in the southeastern US.
Facility Details and Timeline
The planned facility will span 35,000 square feet and is described as a state-of-the-art, purpose-built site. Construction is scheduled for completion, with the plant becoming operational by 2029. This site will join Novartis’s existing RLT manufacturing network in the US, which includes facilities in Indiana and New Jersey, and a recently completed plant in California. The company has also indicated plans for a fifth US location.
Strategic Importance
Radioligand therapy is a precision treatment that combines a tumor-targeting molecule with a therapeutic radioisotope to deliver radiation directly to cancer cells. Each dose is prepared individually and is highly time-sensitive, making the proximity of manufacturing sites to treatment centers critical for timely delivery. The Florida location was selected to optimize the supply chain for patients in the region. Novartis noted Florida’s investment in life sciences education and its growing skilled workforce as key factors in the decision.
About this company
Novartis is an innovative medicines company focused on developing treatments to improve and extend people’s lives. The company states its medicines reach nearly 300 million people worldwide. It is the sole company with two FDA-approved radioligand therapy treatments and maintains an extensive pipeline of RLTs being investigated for various cancer types, including prostate, breast, colon, and lung cancer.
Read more
Novartis Kisqali Gets Positive Chmp Opinion For Reducing Recurrence In Breast Cancer
FDA Approves Novartis’s Kisqali For High-Risk Early Breast Cancer
Novartis Launches Tender Offer to Acquire Tourmaline Bio for $48 Per Share
—
Related Topics
Oktoberfest Closed Amid Bomb Threat Linked to Northern Munich Incident